tbuckley/cabot-search huggingface dataset:
CD73 (ecto-5′-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation
Authors: Natasha T. Snider, Nicholas W. Griggs, Amika Singla, David S. Moons, Sujith V.W. Weerasinghe, Anna S. Lok, Chunhai Ruan, Charles F. Burant, Hari S. Conjeevaram, Bishr M. Omary
Journal: Hepatology (2013)

Formation of hepatocyte Mallory-Denk bodies (MDBs), which are aggregates of keratins 8 and 18 (K8/K18), ubiquitin, and the ubiquitin-binding protein, p62, has a genetic predisposition component in humans and mice. We tested the hypothesis that metabolomic profiling of MDB-susceptible C57BL and MDB-resistant C3H mouse strains can illuminate MDB-associated pathways. Using both targeted and unbiased metabolomic analyses, we demonstrated significant differences in intermediates of purine metabolism. Further analysis revealed that C3H and C57BL livers differ significantly in messenger RNA (mRNA) level, protein expression, and enzymatic activity of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly lower in C57BL livers. CD73 mRNA levels were also dramatically decreased in human liver biopsies from hepatitis C and nonalcoholic fatty liver disease patients. Feeding mice with a diet containing the MDB-inducing agent, 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), significantly decreased CD73 protein and activity in C57BL livers and resulted in loss of plasma membrane CD73 expression and activity in isolated mouse hepatocytes. To further examine the role of CD73 in MDB formation in vivo, we fed wild-type (WT) and CD73(-/-) mice a DDC-containing diet. Liver enlargement, p62 induction, and disappearance of the K8/K18 cytoskeleton were attenuated in CD73(-/-) , compared to WT livers. MDB formation, as assessed by biochemical and immunofluorescence detection of keratin and ubiquitin complexes, was nearly absent in CD73(-/-) mice.Purine metabolism and CD73 expression are linked to susceptibility to MDB formation in livers of different mouse strains. Expression of the adenosine-generating enzyme, CD73, contributes to experimental MDB induction and is highly regulated in MDB-associated liver injury in mice and in chronic human liver disease.
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
Authors: KR Bridges, GD Barabino, C Brugnara, MR Cho, GW Christoph, G Dover, BM Ewenstein, DE Golan, CR Guttmann, J Hofrichter, RV Mulkern, B Zhang, WA Eaton
Journal: Blood (1996)
Eccrine syringofibroadenoma developing in a sebaceous naevus
Authors: M. Noguchi, M. Akiyama, M. Kawakami, T. Nagashima, K. Niizuma, I. Matsuo
Journal: British Journal of Dermatology (2000)

Journal Article Eccrine syringofibroadenoma developing in a sebaceous naevus Get access M. Noguchi, M. Noguchi Search for other works by this author on: Oxford Academic Google Scholar M. Akiyama, M. Akiyama E‐mail: akiyama@med.teikyo‐u.ac.jp Search for other works by this author on: Oxford Academic Google Scholar M. Kawakami, M. Kawakami Search for other works by this author on: Oxford Academic Google Scholar T. Nagashima, T. Nagashima Departments of Dermatology and Neurosurgery, Teikyo University School of Medicine, Ichihara Hospital, 3426–3 Anesaki, Ichihara, Chiba 299–0111, Japan Search for other works by this author on: Oxford Academic Google Scholar K. Niizuma, K. Niizuma Noborito Dermatology Clinic, Kawasaki, Kanagawa 214–0013, Japan Search for other works by this author on: Oxford Academic Google Scholar I. Matsuo I. Matsuo Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 5, 1 May 2000, Pages 1050–1051, https://doi.org/10.1046/j.1365-2133.2000.03498.x Published: 01 May 2000
Abstract 17755: Cardiac Myosin Binding Protein C Contributes to the Protection of the Heart During Immune Response to Infection
Authors: Giuseppina Dusio, Yang Liu, Richard P Tobin, Sanjib Mukherjee, Dhriti Mukhopadhyay, Paola C Rosas, Martha K Newell Rogers, Carl W Tong
Journal: Circulation (2014)

Infections can exacerbate heart failure and contribute to heart transplant rejection. We hypothesize that cardiac myosin binding protein C (MyBPC3), a thick filament protein, contributes to protection of the heart during an immune response to infection. We tested our hypothesis by comparing wild type (WT) vs. MyBPC3(-/-) mice for their immunologic response to non-pathogenic doses of Eschericia coli lipopolysaccharide (LPS). LPS caused increased hypertrophy, worsening of diastolic dysfunction, and increased apoptosis in MyBP3(-/-) hearts. We then performed flow cytometric analyses on immune cells isolated from the myocardium, the spleen, and the bone marrow. Prior to LPS challenge, MyBPC3(-/-) hearts have relatively fewer myeloid cells characterized by CD11b+GR1High in comparison to WT hearts. LPS challenge dramatically increased myeloid cell population in WT, but not in MyBPC3(-/-) hearts. Thus, myeloid population demonstrated inverse relationship with cardiac dysfunction and apoptosis. LPS increased B cells(CD19+) infiltration into MyBPC3(-/-) hearts only, suggesting that increases in B cells correlate with increased cardiac myocyte cell death. In spleen, LPS increased total number of immune cells of all types (CD45+) only in WT. MyBPC3(-/-) showed depressed myeloid cell populations in spleen and bone marrow. Thus, loss of MyBPC3 may have contributed to overall decreased myeloid population. These results suggest that CD11b+GR1High cells are myeloid derived suppressor cells (MDSC) which protect cardiac myocytes during an immune response, and B cells are associated with cardiac myocyte cell death. Furthermore, MyBPC3 may be necessary to recruit MDSCs to maintain protection of the heart during infection. Finally, these results imply that modulating recruitment of MDSCs and preservation of MyBPC3 may provide the basis for new treatments to prevent infection-associated exacerbation of heart failure and heart transplant rejection.
Can Meningococcal C Conjugate Vaccine Overcome Immune Hyporesponsiveness Induced by Previous Administration of Plain Polysaccharide Vaccine?
Authors: Robert J. L. Waugh
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans
Authors: M. Hellerstein, M.B. Hanley, D. Cesar, S. Siler, C. Papageorgopoulos, E. Wieder, D. Schmidt, R. Hoh, R. Neese, D. Macallan, S. Deeks, J.M. McCune
Journal: Nature Medicine (1999)
Abstract 10961: Coronary Flow Reserve Predicts Cardiovascular and Cerebrovascular Events in Patients with Chronic Kidney Disease
Authors: Nobuo Sakamoto, Kazuhiko Nakazato, Syouji Iwaya, Takushi Owada, Yuichi Nakamura, Hiroyuki Yamauchi, Hiroyuki Kunii, Hitoshi Suzuki, Shu-ichi Saito, Toshiyuki Ishibashi, Yasuchika Takeishi
Journal: Circulation (2010)

Purpose: Coronary flow reserve (CFR) provides essential information about the coronary microvascular bed in the absence of epicardial coronary artery narrowing. The reduction of CFR may contribute ...
Abstract 203: Inhibiting invasion and stemness in glioblastoma by thymosin beta 4 gene silencing: a new therapeutic target
Authors: Hans-Georg Wirsching, Shanmugarajan Krishnan, Ana-Maria Florea, Karl Frei, Niklaus Krayenbühl, Kathy Hasenbach, Guido Reifenberger, Michael Weller, Ghazaleh Tabatabai
Journal: Cancer Research (2014)

Abstract Glioblastoma are incurable primary brain tumors with one of the worst 5-year survival rate among all cancers. Despite multimodality treatment involving neurosurgical intervention, radiation and temozolomide chemotherapy, the median overall survival is in the range of 15-16 months. Four large phase III trials investigating dose-dense temozolomide (RTOG0525) or the addition of the integrin inhitibor cilengitide (CENTRIC) or the addition of vascular endothelial growth factor (VEGF) antibody bevacizumab (RTOG 0828, AVAglio) to the current standard treatment failed to extend this range. Novel therapeutic targets are urgently needed. Thymosin beta 4 (TB4) is a pleiotropic actin-sequestering polypeptide that is involved in wound healing and developmental processes. TB4 gene silencing promotes differentiation of neural progenitor cells whereas TB4 overexpression initiates cortical folding of developing brain hemispheres. Moreover, TB4 is involved in migration invasion and epithelial to mesenchymal transition in other cancer entities, e.g. colon cancer. In the present study, we investigated the role of TB4 in malignant glioma. TB4 expression increased with the grade of malignancy in gliomas and correlated with patient survival. In vitro, TB4 gene silencing decreased migration, invasion, growth and self-renewal, and promoted differentiation and the susceptibility to undergo apoptotic cell death upon nutrient depletion in LNT-229, U87MG and the glioma stem-cell line GS2, respectively. In vivo, survival of nude mice bearing tumors derived from TB4-depleted glioma cells was improved and the tumorigenicity of the GS2 glioma-initiating cell line was diminished. The gene expression pattern in TB4-silenced glioma cells was shifted from the mesenchymal towards the pro-neural gene signature. The clustering of differentially regulated genes involved TGF-beta and p53 signaling networks. Taken together, our data indicate that TB4 may be a novel regulator of malignancy in glioblastoma and therefore a candidate therapeutic target. Citation Format: Hans-Georg Wirsching, Shanmugarajan Krishnan, Ana-Maria Florea, Karl Frei, Niklaus Krayenbühl, Kathy Hasenbach, Guido Reifenberger, Michael Weller, Ghazaleh Tabatabai. Inhibiting invasion and stemness in glioblastoma by thymosin beta 4 gene silencing: a new therapeutic target. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 203. doi:10.1158/1538-7445.AM2014-203
Hepatocellular carcinoma with normal adjacent liver
Authors: Patrick Marcellin, Valerie Thiers, Claude Degott, Dominique Franco, Jacques Belghitti, Denis Castaing, Pierre Fagnioz, Serge Zafrani, Jean-Pierre Benhamou, Henri Bismuth, Pierre Tiollais, Christian Bréchot
Journal: Journal of Hepatology (1989)
Allergic cross‐reactions between cat and pig serum albumin
Authors: C. Hilger, M. Kohnen, F. Grigioni, C. Lehners, F. Hentges
Journal: Allergy (1997)

After observing a patient allergic to cat dander and pork but devoid of other allergies, we prospectively screened patients known to be allergic to cat for a second sensitization to pork. After collecting the sera of 10 young patients found to contain specific IgE to cat dander and pork, we undertook this study to detect the possible cross‐reactive allergen, define its molecular characteristics, and evaluate its clinical relevance. Through immunoblotting techniques, cat and porcine serum albumin were found to be jointly recognized molecules. These findings were further analyzed by specific anti‐albumin IgE titrations and cross‐inhibition experiments. Cat serum albumin cDNA was obtained from cat liver, and the corresponding amino acid sequence was deduced and compared to the known porcine and human serum albumin sequences. Inhibition experiments showed that the spectrum of IgE reactivity to cat serum albumin completely contained IgE reactivity to porcine serum albumin, suggesting that sensitization to cat was the primary event. In two cohorts of cat‐allergic persons, the frequency of sensitization to cat serum albumin was found to lie between 14% and 23%. Sensitization to porcine albumin was found to lie between 3% and 10%. About 1/3 of these persons are likely to experience allergic symptoms in relation to pork consumption. Sensitization to cat serum albumin should be considered a useful marker of possible cross‐sensitization not only to porcine serum albumin but also to other mammalian serum albumins.
Arthritis Medications and Cardiovascular Events
Authors: David F Lehmann
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influence of Fluorescein Angiography on the Diagnosis and Management of Retinopathy of Prematurity
Authors: Michael A. Klufas, Samir N. Patel, Michael C. Ryan, Mrinali Patel Gupta, Karyn E. Jonas, Susan Ostmo, Maria Ana Martinez-Castellanos, Audina M. Berrocal, Michael F. Chiang, R.V. Paul Chan
Journal: Ophthalmology (2015)
Abstract 1568: Cellular mechanisms of tumor regression following Myc inhibition
Authors: Dan Lu, Deborah L. Burkhart, Julian L. Griffin, Trevor D. Littlewood, Gerard I. Evan
Journal: Cancer Research (2014)

Abstract Myc is a pleiotropic transcription factor associated with various aspects of cell growth. Tumor cells often have deregulated Myc expression, which consequently promotes uncontrolled proliferation. Recent work in our lab using a mouse model of lung cancer has demonstrated that expression of a dominant negative form of Myc causes tumor regression whilst having mild and reversible effects on normal proliferating tissues. However the cellular mechanism of how Myc inhibition leads to tumor regression is not known. Here we show that Myc inhibition causes metabolic changes in tumor cells associated with a reduced proliferative/biosynthetic state. Furthermore, we demonstrate that Myc inhibition leads to p21 expression independently of p53 and may account for tumor cell cycle arrest. Citation Format: Dan Lu, Deborah L. Burkhart, Julian L. Griffin, Trevor D. Littlewood, Gerard I. Evan. Cellular mechanisms of tumor regression following Myc inhibition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1568. doi:10.1158/1538-7445.AM2014-1568
698. Gene Therapy of Murine GM1 Gangliosidosis by Genetically Modified Bone Marrow Hematopoietic Progenitor Cells
Authors: Renata Sano, Alessandra Tessitore, Angela Ingrassia, Alessandra d'Azzo
Journal: Molecular Therapy (2004)

b-galactosidase (b-gal), a lysosomal enzyme involved  the removal of b-linked terminal galactosyl residues of many glycoconjugates, is deficient  the neurodegenerative lysosomal disorder GM1-gangliosidosis (GM1). GM1-/-mice closely mimic the most fundamental aspects of the neuropathological and neurochemical abnormalities of the human disorder. Bone marrow progenitor cells have been used as a source of corrective protein because of their ability to repopulate the recipients and to supply functional enzyme to different cells by in trans correction. Hematopoietic progenitors transduced with a murine stem cell virus (MSCV)-based bicistronic retroviral vector over-expressing b-gal and the green fluorescent protein (GFP) marker were used for transplantation into sublethally irradiated GM1-/-mice. Transduction efficiency of total BM cells with the MSCV-b-gal ranged from 25–89% prior to the transplantation. b-gal expressing BM-derived cells were detected histologically and enzymatically  many tissues including spleen, liver, lungs, intestine and kidney after one, three and six months post transplantation (BMT). GFP-expressing cells of the erythroid, myeloid or lymphoid lineage were identified by FACS analysis of peripheral blood samples, collected at different time points after transplantation. Secondary transplantations demonstrated consistent long-term in vivo b-gal expression  all tissues including brain. In addition, the thin layer chromatography of brain lipids showed a reduction  the GM1-ganglioside content  brainstem and cerebellum after three and six months post BMT. In line with the biochemical and histological findings, different behavioral tests including open field, rotorod and walking pattern, indicated a clear improvement of the neurological function  transplanted GM1-/-compared to untreated littermates. Taken together these results have encouraged the use of ex-vivo gene therapy for the treatment of GM1.
857. Intravenous Retroviral Gene Therapy in Neonatal Mucopolysaccharidosis VI Cats
Authors: Thomas M. O'Malley, YuLi Liu, Patty A. O'Donnell, Karyn J. Cullen, Ping Wang, Kristen J. Cullen, Gustavo D. Aguirre, Katherine P. Ponder, Mark E. Haskins
Journal: Molecular Therapy (2004)

Mucopolysaccharidosis (MPS) VI is a lysosomal storage disease caused by deficient activity of N-acetylgalactosamine 4-sulfatase (4S) resulting in an inability to degrade the glycosaminoglycan (GAG) dermatan sulfate, which accumulates in the lysosomes. Clinical features include skeletal abnormalities, growth retardation, facial dysmorphia, and corneal clouding. Two MPS VI cats were injected intravenously at 4 days of age with a Moloney murine leukemia virus-based retroviral vector containing the human alpha-1-antitrypsin promoter, the feline 4S (f4S) cDNA (kindly provided by John J. Hopwood), and the woodchuck hepatitis virus posttranscriptional regulatory element. Both animals received 7.2X10E9 transducing units/kg of body weight. Stable f4S activity has been detected in serum throughout the study and the most recent values from samples taken at 6 months were 23 and 9 times normal. The f4S activities in liver biopsies taken at 5 months were 82 and 38 times normal and the concentration of GAG in the biopsies was reduced to normal levels, 1.2 and 1.8 ug/mg protein, respectively. In comparison, the GAG concentration in liver biopsies from the untreated MPS VI littermates was 34.9 and 20.6 ug/mg. The body weights of the treated cats are 130% and 122% that of their two untreated MPS VI sex-matched control littermates (average of 1.89 kg) and are not different from normal unrelated age- and sex-matched controls. There are profound differences in the appearance of the treated and untreated cats. The MPS VI controls have short ears and tails and their faces are broad and flat. They have joint stiffness and major locomotor difficulties. The treated cats have only mild facial dysmorphia, a much freer range of pelvic motion, near normal gaits, and are more physically active than their MPS VI littermates. The cat with the higher f4S activity is nearly indistinguishable from a phenotypically normal cat except for the eyes, as there was no significant improvement in corneal clouding. MPS VI is particularly suited to liver-directed therapy because unlike other MPS disorders, CNS involvement is minimal. Because MPS VI is a progressive disease, the full extent of the clinical benefit will only become evident over time. We will present a 10-month update, including radiographs comparing the skeletons of normal, treated, and untreated MPS VI cats.
Abstract 15413: Increased Body Mass Index is Associated with Greater Prevalence, Extent, and Severity of Coronary Artery Disease and Increased Adverse Events
Authors: Troy M LaBounty, Millie Gomez, Stephen Achenbach, Mouaz Al-Mallah, Daniel S Berman, Matthew J Budoff, Filippo Cademartiri, Tracy Q Callister, Hyuk-Jae Chang, Victor Cheng, Kavitha M Chinnaiyan, Benjamin J Chow, Augustin Delago, Allison M Dunning, Martin Hadamitzky, Joerg Hausleiter, Ronald P Karlsberg, Philipp A Kaufmann, Jonathon Leipsic, Fay Y Lin, Erica Maffei, Gilbert Raff, Leslee J Shaw, Todd Villines, James K Min
Journal: Circulation (2011)

Introduction: Higher body mass index (BMI) is associated with increased cardiac risk factors, but its relationship with incident coronary artery disease (CAD) and adverse events is not clear. Metho...